What is Leerink Partnrs’ Estimate for BPMC FY2025 Earnings?

Blueprint Medicines Co. (NASDAQ:BPMC) – Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for Blueprint Medicines in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings per share of ($1.24) for the year, down from their previous forecast of ($0.99). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.63) per share.

A number of other research firms have also weighed in on BPMC. Guggenheim reissued a “buy” rating on shares of Blueprint Medicines in a research report on Wednesday, December 11th. StockNews.com upgraded Blueprint Medicines from a “sell” rating to a “hold” rating in a research note on Friday, November 8th. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Wells Fargo & Company reduced their price objective on Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 target price on shares of Blueprint Medicines in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $123.72.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock opened at $101.57 on Monday. Blueprint Medicines has a 1-year low of $72.24 and a 1-year high of $121.90. The firm has a fifty day simple moving average of $99.51 and a 200-day simple moving average of $94.71. The company has a current ratio of 3.32, a quick ratio of 3.27 and a debt-to-equity ratio of 1.09. The stock has a market capitalization of $6.45 billion, a price-to-earnings ratio of -48.14 and a beta of 0.62.

Insider Activity

In other Blueprint Medicines news, COO Christina Rossi sold 2,274 shares of the company’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $95.10, for a total transaction of $216,257.40. Following the sale, the chief operating officer now directly owns 71,657 shares of the company’s stock, valued at approximately $6,814,580.70. This represents a 3.08 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kate Haviland sold 2,353 shares of Blueprint Medicines stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $96.60, for a total transaction of $227,299.80. Following the completion of the transaction, the chief executive officer now owns 150,824 shares of the company’s stock, valued at $14,569,598.40. This trade represents a 1.54 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,851 shares of company stock worth $4,984,696. Corporate insiders own 4.21% of the company’s stock.

Hedge Funds Weigh In On Blueprint Medicines

A number of institutional investors have recently modified their holdings of BPMC. Pallas Capital Advisors LLC lifted its holdings in Blueprint Medicines by 3.2% during the 3rd quarter. Pallas Capital Advisors LLC now owns 5,657 shares of the biotechnology company’s stock worth $523,000 after buying an additional 176 shares in the last quarter. Torray Investment Partners LLC raised its position in shares of Blueprint Medicines by 1.1% during the fourth quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company’s stock worth $1,439,000 after acquiring an additional 186 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of Blueprint Medicines by 0.7% during the third quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company’s stock valued at $3,259,000 after acquiring an additional 265 shares during the period. Hillsdale Investment Management Inc. boosted its holdings in Blueprint Medicines by 0.6% in the fourth quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company’s stock valued at $4,433,000 after acquiring an additional 310 shares during the last quarter. Finally, Quarry LP acquired a new stake in Blueprint Medicines in the third quarter worth about $32,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.